Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

Highlights Launched Vision 2030Delivered Adjusted EBITDA margin of 19.1%Returned to positive packaging volume growth in second half of the yearAchieved Innovation Sales Growth of $205 millionExecuted ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter ...

MIAMI, FL / ACCESS Newswire / February 4, 2025 / For decades, companies and policymakers have relied on carbon credits as a tool to combat environmental challenges. Yet, carbon credits have proven to ...

The company has made significant strides with its phase 1 INSIGHT-003 study, which assessed the combination of efti, KEYTRUDA ... is a global packaging company specializing in the development ...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda ... of a superior data package, including stability data ...

Both Opdivo and Keytruda are still in the foothills of ... However shareholders have raised questions about the compensation package of Vertex's CEO, Jeffrey Leiden, which topped $28 million ...

Keytruda and Lenvima with chemotherapy improved progression-free survival and objective response rate but not overall survival in HER2-negative gastroesophageal adenocarcinoma. The safety profile of ...

A global phase 3 trial is evaluating ASP-1929 photoimmunotherapy with Keytruda for recurrent HNSCC, involving around 400 patients. ASP-1929, an antibody-dye conjugate targeting EGFR, is activated by ...

4Q Earnings: $3.7 billion (loss of $1.2 billion 4Q23) FY Earnings: $17.1 billion (earnings were $365 million FY23) ...